Sun Pharmaceutical Industries Gets CDSCO Panel Nod to Study FDC of Relugolix, Estradiol, Norethindrone Acetate
Written By : Dr. Divya Colin
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-04-08 12:30 GMT | Update On 2024-04-08 12:30 GMT
Advertisement
New Delhi: Rejecting for clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) opined the pharmaceutical major Sun Pharmaceutical Industries to conduct of Phase III clinical trial of the fixed-dose combination (FDC) of Relugolix, Estradiol and Norethindrone Acetate Tablets (40 mg + 1 mg + 0.5 mg) Tablets.
This came after the drug major Sun Pharmaceutical Industries presented the proposal before the committee for CT waiver and the published safety and efficacy data.
The committee did not agree to the clinical trial waiver and the firm was asked to present Phase III CT protocol in continuation with an earlier SEC recommendation dated 19th December 2023.
In continuation with the above, the committee recommended for conducting the Phase III clinical trial as per the protocol presented by the firm.
Relugolix is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication that is used in the treatment of prostate cancer in men and uterine fibroids in women.
At the recent SEC meeting for the Reproductive held on 20th March 2024, the expert panel reviewed the proposal presented by the drug major Sun Pharmaceutical Industries regarding the FDC Relugolix, Estradiol, and Norethindrone Acetate Tablets.
After detailed deliberation, the committee recommended the conducting of a Phase III clinical trial as per the protocol presented by the firm.
Also Read: Eli Lilly Gets CDSCO Panel Nod To Market Mirikizumab for ulcerative colitis in adults
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.